Yvonne T. Daniel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yvonne T. Daniel has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin P. Martin
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
1 shared publication - Jennifer R. Devlin
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
1 shared publication - Nenad Bartonicek
Garvan Institute of Medical Research 1 Cancer Ecosystems Program Darlinghurst, Australia
1 shared publication - Ricky W. Johnstone
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
1 shared publication
Latest Publications
- Open Access
- 30 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF17
Sensitivity of Pancreatic Adenocarcinoma Cells to Blockade of Post-initiation CDK-Dependent Pol II Transcription Cycle Checkpoints
Pancreatic adenocarcinoma (PDAC) is a leading cause of cancer-related morbidity, with oncogenic KRAS/MAPK/ERK signaling arising from activating KRAS mutations being the key feature of this malignancy. Dysregulation of RNA polymerase II (Pol II)–dependent transcription is a universal hallmark of cancers, including PDAC, with aberrant gene expression programs driving tumorigenesis and influencing therapy response. Pol II progression through multiple transcription cycle checkpoints depends on transcriptional cyclin-dependent kinases (tCDK), and targeted inhibition of distinct tCDKs has been shown to be a promising anticancer strategy. In this study, we profile biological and molecular PDAC cell responses to selective blockade of tCDK kinase activity at all Pol II transcription cycle checkpoints, alone and in combination with inhibitors of mutant KRAS or MEK. We identify post–transcription-initiation checkpoints controlled by CDK9, CDK11, and CDK12/13 as critical for nascent gene expression and cell proliferation in PDAC. However, although dual targeting of tCDK and KRAS/MAPK/ERK networks amplifies transcriptomic phenotypes, this results in limited cooperative therapeutic impacts.
- 30 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF17
Open AccessSensitivity of Pancreatic Adenocarcinoma Cells to Blockade of Post-initiation CDK-Dependent Pol II Transcription Cycle Checkpoints
Pancreatic adenocarcinoma (PDAC) is a leading cause of cancer-related morbidity, with oncogenic KRAS/MAPK/ERK signaling arising from activating KRAS mutations being the key feature of this malignancy. Dysregulation of RNA polymerase II (Pol II)–dependent transcription is a universal hallmark of cancers, including PDAC, with aberrant gene expression programs driving tumorigenesis and influencing therapy response. Pol II progression through multiple transcription cycle checkpoints depends on transcriptional cyclin-dependent kinases (tCDK), and targeted inhibition of distinct tCDKs has been shown to be a promising anticancer strategy. In this study, we profile biological and molecular PDAC cell responses to selective blockade of tCDK kinase activity at all Pol II transcription cycle checkpoints, alone and in combination with inhibitors of mutant KRAS or MEK. We identify post–transcription-initiation checkpoints controlled by CDK9, CDK11, and CDK12/13 as critical for nascent gene expression and cell proliferation in PDAC. However, although dual targeting of tCDK and KRAS/MAPK/ERK networks amplifies transcriptomic phenotypes, this results in limited cooperative therapeutic impacts.